Bivirkninger var almindelige (≥ 1/ 100 til < 1/ 10) i kliniske undersøgelser hos patienter behandlet med ViraferonPeg monoterapi.
These adverse reactions were common (≥1/100 to < 1/10) in clinical trials in patients treated with ViraferonPeg monotherapy.